Date | Time | Source | Announcement |
---|---|---|---|
24 May 2007 | 07:01 AM | FBR Growth Conference | |
22 May 2007 | 03:53 PM | Holding(s) in Company | |
17 May 2007 | 01:23 PM | Blocklisting 6 monthly return | |
17 May 2007 | 07:00 AM | Phase II Date @ AAI Meeting | |
08 May 2007 | 07:01 AM | Development of OVA System | |
03 May 2007 | 11:59 AM | AGM 2007 | |
01 May 2007 | 07:01 AM | Preclinical data | |
30 Apr 2007 | 04:07 PM | TVR update | |
30 Apr 2007 | 04:05 PM | Holding(s) in Company | |
30 Apr 2007 | 07:01 AM | Director/PDMR Shareholding | |
17 Apr 2007 | 04:02 PM | Annual Information Update | |
05 Apr 2007 | 03:29 PM | Holding(s) in Company | |
03 Apr 2007 | 04:30 PM | Director/PDMR Shareholding | |
30 Mar 2007 | 02:32 PM | Total Voting Rights | |
29 Mar 2007 | 02:30 PM | Notice of AGM | |
28 Mar 2007 | 07:01 AM | Agreement to develop Trovax | |
20 Mar 2007 | 06:05 PM | Holding(s) in Company | |
16 Mar 2007 | 05:31 PM | Holding(s) in Company | |
16 Mar 2007 | 01:35 PM | Holding(s) in Company | |
15 Mar 2007 | 08:42 AM | Acquisition | |
12 Mar 2007 | 07:01 AM | Acq of Oxxon Therapeutics | |
06 Mar 2007 | 07:00 AM | Preliminary Results | |
28 Feb 2007 | 11:15 AM | Total Voting Rights | |
27 Feb 2007 | 11:12 AM | Holding(s) in Company | |
27 Feb 2007 | 07:00 AM | Notice of FY2006 Results | |
22 Feb 2007 | 09:36 AM | Holding(s) in Company | |
20 Feb 2007 | 12:45 PM | Holding(s) in Company | |
14 Feb 2007 | 11:04 AM | Holding(s) in Company | |
09 Feb 2007 | 10:55 AM | Holding(s) in Company | |
07 Feb 2007 | 05:49 PM | Holding(s) in Company | |
01 Feb 2007 | 03:18 PM | Result of EGM | |
31 Jan 2007 | 06:04 PM | Total Voting Rights | |
24 Jan 2007 | 03:39 PM | Holding(s) in Company | |
24 Jan 2007 | 07:00 AM | Transgenic Milestone | |
16 Jan 2007 | 07:01 AM | Publication of Results | |
10 Jan 2007 | 07:00 AM | Phase III Trial of Trovax | |
04 Jan 2007 | 04:48 PM | Total Voting Rights-Amendment | |
02 Jan 2007 | 03:47 PM | Total Voting Rights-Amendment | |
22 Dec 2006 | 11:55 AM | Total Voting Rights | |
21 Dec 2006 | 07:00 AM | GSK Lentivector Licence | |
19 Dec 2006 | 05:51 PM | Holding(s) in Company | |
19 Dec 2006 | 07:00 AM | Licensing Agreement | |
08 Dec 2006 | 04:55 PM | Holding(s) in Company | |
08 Dec 2006 | 07:00 AM | Positive Opinion on Trovax | |
05 Dec 2006 | 07:00 AM | Holding(s) in Company | |
21 Nov 2006 | 09:31 AM | Blocklisting Interim Review | |
13 Nov 2006 | 07:00 AM | Prosavin preclinical data | |
09 Nov 2006 | 07:00 AM | Phase II Results - Trovax | |
07 Nov 2006 | 07:00 AM | Phase III Trial in Trovax | |
06 Oct 2006 | 07:00 AM | Presentation at Conference |
Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.
Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.
Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.